生物增强联合孤立半月板修复与同期前交叉韧带重建的半月板修复结局相当
本队列研究比较了109例骨骼成熟患者中,采用髁间窝骨髓开窗(MVP)生物增强的孤立半月板修复(37膝)与同期前交叉韧带(ACL)重建的半月板修复(72膝)的结局与生存率。两组所有结局评分均显著改善且无显著差异,总体失败率为9.5%(9/95),两组失败率无显著差异(P=.429)。失败与女性性别显著相关(P=.001)。
要点
- MVP生物增强的孤立半月板修复与同期ACL重建的半月板修复在术前及术后所有结局评分上无显著差异。
- 总体失败率为9.5%(9/95),MVP组失败率12.9%(4/37)与ACL重建组7.8%(5/72)无显著差异(P=.429)。
- 失败与女性性别显著相关(P=.001)。
核心结论
- 采用髁间窝骨髓开窗(MVP)生物增强的半月板修复与同期前交叉韧带(ACL)重建的半月板修复在结局上无差异。
- MVP半月板修复与ACL重建半月板修复的相似结局可能部分归因于生物增强。
研究设计与样本
- 队列研究,证据等级3级。
- 纳入标准为骨骼成熟、年龄≥16岁、接受由内向外半月板修复并同期行髁间窝MVP或ACL重建的患者。
- 排除骨骼未成熟、半月板根部或放射状撕裂修复、或同期非限于ACL的韧带重建者。
- 共109例患者(52女,57男),队列1(孤立半月板修复+MVP)37膝,队列2(半月板修复+ACL重建)72膝。
- 失败状态已知95例,获得患者报告结局评分89例(82%)。
主要发现
- 两队列所有结局评分均显著改善,且术前及术后任何结局测量均无显著差异。
- 总体失败率为9.5%(9/95)。
- 队列1失败4例(12.9%),队列2失败5例(7.8%),两组失败无显著差异(P=.429)。
- 失败与女性性别显著相关(P=.001)。
关键数值与推荐
- 失败定义为再手术行半月板切除或翻修半月板修复。
- 总体失败率9.5%(9/95)。
- 队列1失败率12.9%(4/37),队列2失败率7.8%(5/72),组间比较P=.429。
- 失败与女性性别相关P=.001。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Meniscal repair in the setting of anterior cruciate ligament (ACL) reconstruction has demonstrated superior outcomes compared with isolated meniscal repair. Limited evidence exists for the effects of biological augmentation in isolated meniscal repair, particularly as compared with meniscal repair with concomitant ACL reconstruction. Purpose/Hypothesis: The purpose of this study was to compare the outcomes and survivorship of meniscal repair in 2 cohorts of patients: meniscal repair with biological augmentation using a marrow venting procedure (MVP) of the intercondylar notch, and meniscal repair with concomitant ACL reconstruction. We hypothesized that the clinical outcomes and survivorship of meniscal repair with concomitant ACL reconstruction would be improved compared with meniscal repair with biological augmentation. STUDY DESIGN: Cohort study; Level of evidence, 3. METHODS: Inclusion criteria were skeletally mature patients aged ≥16 years who underwent inside-out meniscal repair and either a concomitant MVP of the intercondylar notch or ACL reconstruction. Patients were excluded from this study if they were skeletally immature, underwent meniscus root or radial tear repair, or underwent meniscal repair with concurrent ligamentous reconstruction not limited to the ACL. At the preoperative evaluation and a minimum 2 years after the index meniscal repair procedure, patients were administered a subjective questionnaire. Differences in outcome scores, survivorship, and failure rates between the cohorts were assessed. Failure was defined as reoperation with meniscectomy or revision meniscal repair. RESULTS: There were 109 patients (52 female, 57 male) who met the inclusion criteria for this study. There were 37 knees in cohort 1 (isolated meniscal repair plus MVP) and 72 knees in cohort 2 (meniscal repair plus ACL reconstruction). The failure status was known in 95 patients, and patient-reported outcome scores were obtained in 89 (82%) patients. Both cohorts demonstrated a significant improvement in all outcome scores, and there was no significant difference in any of the preoperative or postoperative outcome measures. The overall failure rate was 9.5% (9/95). There were 4 (12.9%) failures in cohort 1 and 5 failures (7.8%) in cohort 2, with no significant difference in failures between the cohorts ( P = .429). There was a significant association between failure and female sex ( P = .001). CONCLUSION: The most important finding in this study was that there was no difference in outcomes in meniscal repair performed with biological augmentation using an MVP versus that performed concomitantly with ACL reconstruction. The similar outcomes reported for meniscal repair with an MVP and meniscal repair with ACL reconstruction may be partly attributed to biological augmentation.
引用
- Dean CS, Chahla J, Matheny LM, et al. Outcomes After Biologically Augmented Isolated Meniscal Repair With Marrow Venting Are Comparable With Those After Meniscal Repair With Concomitant Anterior Cruciate Ligament Reconstruction. Am J Sports Med. 2017. PMID: 28298056. doi:10.1177/0363546516686968
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。